<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02739659</url>
  </required_header>
  <id_info>
    <org_study_id>SPHIC-TR-PCa 2015-01</org_study_id>
    <nct_id>NCT02739659</nct_id>
  </id_info>
  <brief_title>Carbon Ion Radiotherapy for the Treatment of Localized Prostate Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Proton and Heavy Ion Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Proton and Heavy Ion Center</source>
  <brief_summary>
    <textblock>
      The aim of this research project is to assess the feasibility and safety of carbon-ion&#xD;
      radiotherapy (CIRT) for the treatment of in Chinese localized prostate cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the maximal tolerated dose (MTD) of CIRT in the&#xD;
      treatment of localized prostate cancer and to evaluate the efficacy of such treatment at the&#xD;
      MTD. Participants will be treated with CIRT with escalating dose regimens to evaluate the&#xD;
      maximal tolerated dose (MTD) in terms of acute and subacute toxicity observed during and&#xD;
      within 6 months after the completion of CIRT. Once the MTD for localized prostate cancer is&#xD;
      determined, the MTD will be used as the recommended dose to patients fulfilling the inclusion&#xD;
      criteria in the Phase II part of the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>From the date of CIRT to 6 months after the completion of CIRT, up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival of all patients</measure>
    <time_frame>From the diagnosis of localized prostate, a median of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biochemical failure-free survival，bFFS</measure>
    <time_frame>From the completion of CIRT, a median of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival of all patients</measure>
    <time_frame>From the completion of CIRT, a median of 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">73</enrollment>
  <condition>Prostate Carcinoma</condition>
  <arm_group>
    <arm_group_label>carbon-ion radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Five dose levels [59.2 GyE(Gray equivalent)/16Fx, 60.8 GyE/16Fx, 62.4 GyE/16Fx, 64.0 GyE/16Fx and 65.6 GyE/16Fx] are planned within the Phase I part. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 65.6 GyE/16Fx are safely delivered, the recommended dose (or 65.6 GyE/16Fx) will be the prescribed dose in the Phase II part of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>carbon-ion radiotherapy</intervention_name>
    <arm_group_label>carbon-ion radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  No lymph node and distant metastasis&#xD;
&#xD;
          -  Age ≥ 20 and &lt; 85 years of age&#xD;
&#xD;
          -  Karnofsky Performance Score ≥70&#xD;
&#xD;
          -  No previous pelvic radiation therapy (RT)&#xD;
&#xD;
          -  No previous prostatectomy&#xD;
&#xD;
          -  No previous invasive cancer (within 5 years before the prostate cancer&#xD;
             diagnosis)except for skin non-melanoma cancer&#xD;
&#xD;
          -  Ability to understand character and individual consequences of the clinical trial&#xD;
&#xD;
          -  Willing to sign the written informed consent; Informed consent must be signed before&#xD;
             the enrollment in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No pathologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Pelvic lymph node metastasis (N1)&#xD;
&#xD;
          -  Distant metastasis (M1)&#xD;
&#xD;
          -  Urinary obstructive symptoms (IPSS &gt; 20)&#xD;
&#xD;
          -  Previous pelvic radiotherapy&#xD;
&#xD;
          -  Previous prostatectomy&#xD;
&#xD;
          -  Severe systemic disorders&#xD;
&#xD;
          -  Concomitant disorders including: chronic urinary or intestinal inflammatory conditions&#xD;
             (for example, ulcerous recto-colitis, Crohn disease), anti-coagulant treatment&#xD;
             (warfarin, heparin)&#xD;
&#xD;
          -  Previous malignancy except for skin non-melanoma cancer or 3-year disease free&#xD;
             interval from previous malignancy like non muscle invasive bladder cancer&#xD;
&#xD;
          -  Non conformity of the radiotherapy dose distribution when compared to the dose&#xD;
             constraints&#xD;
&#xD;
          -  Psychiatric disorders or any other condition that can make unreliable the informed&#xD;
             consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qing Zhang, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Proton and Heavy Ion Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ping Li, Dr.</last_name>
    <email>ping.li@sphic.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Proton and Heavy Ion Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201321</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Li, Dr.</last_name>
      <email>ping.li@sphic.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Qing Zhang, Dr.</last_name>
      <email>qing.zhang@sphic.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Qing Zhang, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 7, 2016</study_first_submitted>
  <study_first_submitted_qc>April 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Proton and Heavy Ion Center</investigator_affiliation>
    <investigator_full_name>Qing Zhang,MD</investigator_full_name>
    <investigator_title>DIRECTOR</investigator_title>
  </responsible_party>
  <keyword>prostate carcinoma</keyword>
  <keyword>carbon-ion radiotherapy</keyword>
  <keyword>efficacy</keyword>
  <keyword>toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

